查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1351068

2030 年核子医学市场预测：按细分市场和地区分類的全球分析

Nuclear Medicine Market Forecasts to 2030 - Global Analysis By Type, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球核医学市场规模为 103 亿美元，预计预测期内年复合成长率为 13.8%，到 2030 年将达到 255 亿美元。

核子医学是领域。核子医学主要用于需要核子医学诊断和治疗的各种疾病。放射性药物用于治疗。多种疾病都需要这种类型的治疗，包括甲状腺亢进、各种形式的骨痛和甲状腺癌。

据美国心臟协会称，2020 年全球约有 1,910 万人死于 CVD。每10万人口年龄调整死亡率为239.8，年龄调整患病7,354.1。

癌症和心臟疾病患病上升

这种增加的疾病负担需要先进的诊断和治疗方案，其中核子医学发挥关键作用。核子医学提供准确、早期疾病检测、精确治疗监测和标靶治疗的能力正在引起医疗保健提供者和患者的注意。因此，随着健康挑战的加剧，对高效和个体化医疗保健解决方案的需求不断增长，刺激了核医学领域的扩张，推动创新和市场发展。

诊断及治疗设备及程序高成本

核子医学影像和治疗所需的复杂技术和专用材料导致初期成本急剧上升。此外，对熟练人员、维护和法规遵循的需求进一步增加了经济负担。这些高成本阻碍了核子医学服务的取得，并限制了采用率，特别是在资源有限的医疗保健系统中。解决负担能力问题将确保核医学的广泛使用，因为在不牺牲品质的情况下降低成本仍然是市场扩张和公平医疗保健提供的关键因素。这样做极为重要。

对影像导引手术和诊断的需求不断增加

许多大公司和医学都采用了核子医学，因为它改善了他们的生产流程。这些系统能够提高产量、降低成本、提高品质并实现即时资料收集和产品监控，从而提高生产效率。这方面有望鼓励使用这些系统来增加收益。核子医学的使用也减少了整个生产过程中的废弃物和能源使用量。例如，在製造车间安装 MES 解决方案可以消除对文书工作和实体储存空间的需求，同时也消除了对额外 IT 资源的需求。

严格的法规指引

随着产业的发展，遵守复杂且不断变化的法规变得至关重要。这些指南包括安全性、有效性和伦理考虑，并且通常要求新技术和放射性药物经过严格的测试和核准流程。合规性所需的时间和资源可能会阻碍创新、延迟产品发布并增加开发成本。满足这些要求的努力可能会阻止新进入者并限制市场成长。因此，应对法规限制的迷宫已成为一项重大挑战，可能阻碍核医学解决方案的快速发展。

COVID-19 的影响：

COVID-19的爆发对核医学市场产生了重大影响。由于资源重新分配和安全问题，选择性手术和常规影像面临延迟，导致患者数量下降。供应链中断影响了放射性药物和设备的可得性，导致市场波动。然而，这场危机凸显了核子医学在疾病快速诊断和治疗监测方面的价值。远端医疗和远距报告已普及，服务提供也已重组。

预测期内正子断层扫描（PET）应用领域预计最大

正子断层扫描（PET）应用领域预计将出现良好的成长。 PET 可实现体内代谢和功能过程的精确视觉化和量化。 PET 对肿瘤学至关重要，有助于早期发现癌症、准确分期并监测治疗效果。在神经病学中，PET 扫描可用于诊断阿兹海默症和癫痫等脑部疾病。心血管疾病是透过 PET 评估血流和心臟功能的能力来评估的。此外，PET 有助于新放射性药物的开发并支持药物研发研究。 PET 的非侵入性和定量资料使其成为推进个体化和有针对性的医疗干预的基石。

预计医院领域在预测期内的年复合成长率最高。

预计医院领域在预测期内将以最快的年复合成长率成长。核子医学市场的医院是诊断、治疗和研究的主要中心。医院配备了 PET、SPECT 和伽马相机等先进的影像设备，提供核子医学的基本服务。我们为广大患者提供准确的疾病检测、准确的分期和治疗监测。医院内的核子医学部门与多学科团队合作，通常将影像学与其他医学领域整合，以加强患者照护。此外，医院也为创新放射性药物和影像技术的开发和评估做出了重大贡献，促进核子医学的持续进步，改善病患的治疗效果。

占比最大的地区：

在预测期内，由于其先进的医疗基础设施和研究能力，北美核医学市场预计将继续占据大部分市场占有率。该地区成熟的医疗设施和学术机构推动了成像技术和放射性药物开发的创新。癌症和心血管疾病等慢性病的高罹患率正在推动对核医学服务的需求。北美强大的法规结构确保了安全和品质标准。主要市场参与者的存在、与研究机构的合作以及医疗保健投资的增加有助于该地区在核医学的领导地位，使其成为尖端诊断和治疗应用的中心。

复合年复合成长率最高的地区：

由于医疗保健投资的增加、疾病早期检测意识的提高以及老年人口的增长推动了对尖端诊断和治疗解决方案的需求，亚太地区在预测期内将出现最高的年复合成长率，预计这种情况将会发生。该地区扩大医疗基础设施和改善经济状况正在推动核医学技术的采用。此外，亚太地区多样化的患者群体为临床研究和临床试验提供了充足的机会，有助于创新放射性药物和影像技术的研究和开发。凭藉新兴市场和技术进步的结合，亚太地区有望在塑造核医学的未来方面发挥关键作用。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球核子医学市场：依类型

  • 诊断核子医学
    • 单光子发射电脑断层扫描 (SPECT) 放射性药物
      • 锝-99m
      • 碘123
      • 铊201
      • 镓67
    • 正子断层扫描 (PET) 放射性药物
      • 氟18
      • 铷82
  • 治疗性核子医学
    • 阿尔法发射器
      • 镭223
    • β放射体
      • 碘131
      • 钇90
      • 钐-153
      • 镏-177
      • 铼186
  • 近距离放射同位素
    • 碘125
    • 铱192
    • 钯103
    • 铯131
  • 其他类型

第6章全球核子医学市场：依用途

  • 诊断用途
    • 单光子发射电脑断层扫描 (SPECT) 应用
      • 心臟病学
      • 骨骼扫描
      • 甲状腺的应用
      • 肺部扫描
    • 正子断层扫描（PET）的应用
      • 肿瘤学
      • 心臟病学
      • 神经病学
    • 治疗应用
      • 甲状腺适应症
      • 骨转移
      • 淋巴瘤
      • 内分泌肿瘤
  • 其他用途

第7章全球核子医学市场：依最终使用者分类

  • 医院
  • 影像中心
  • 学术研究中心
  • 其他最终用户

第8章全球核子医学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Isotopia Molecular Imaging Ltd.
  • Jubilant Draximage, Inc.
  • Lantheus Holdings, Inc.
  • Cardinal Health
  • Global Medical Solutions
  • Pharmalogic Holdings Corp.
  • Shine Technologies, llc
  • Ire Elit
  • Eczacibasi-Monrol Nuclear Products
  • GE Healthcare
  • Bayer AG
  • Bracco Imaging SPA
  • Nordion Inc.
  • Northstar Medical Radioisotopes
  • Isotope JSC
  • Siemens Healthineers
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Eckert & Ziegler
Product Code: SMRC23755

According to Stratistics MRC, the Global Nuclear Medicine Market is accounted for $10.3 billion in 2023 and is expected to reach $25.5 billion by 2030 growing at a CAGR of 13.8% during the forecast period. Nuclear medicine is a specialty that examines the structure, and occasionally the operation, of an organ in the human body using a very small amount of radiology or other radioactive elements. It is mostly utilized for various disorders that require nuclear medicine for diagnosis and treatment. Radiopharmaceuticals are utilized during the course of the treatment. This kind of treatment is required for a variety of conditions, including hyperthyroidism, various forms of bone pain, and thyroid cancer.

According to American Heart Association 2022, approximately 19.1 million deaths were attributed to CVD globally in 2020. The age-adjusted death rate per 100,000 population was 239.8 and age-adjusted prevalence rate was 7354.1 per 100,000.

Market Dynamics:

Driver:

Rise in prevalence of cancer and cardiac disorders

This rise in disease burden necessitates advanced diagnostic and treatment options, where nuclear medicine plays a pivotal role. The technique's ability to offer accurate and early disease detection, precise treatment monitoring, and targeted therapies has garnered attention from both healthcare providers and patients. As a result, the increasing demand for efficient and personalized healthcare solutions in the face of these mounting health challenges has spurred the expansion of the nuclear medicine sector, driving innovation and market advancement.

Restraint:

High cost of the diagnostic and therapeutic equipment and procedures

The intricate technologies and specialized materials required for nuclear imaging and treatments contribute to elevated upfront expenses. Moreover, the need for skilled personnel, maintenance, and regulatory compliance further amplifies the financial burden. These high costs can impede accessibility to nuclear medicine services, limiting adoption rates, particularly in resource-constrained healthcare systems. Addressing the affordability challenge becomes pivotal to ensuring wider utilization of nuclear medicine, as reducing costs without compromising quality remains a critical factor for market expansion and equitable healthcare delivery.

Opportunity:

Increasing demand for image guided procedures and diagnostics

Many major companies and SMEs are implementing Nuclear Medicine because they improve production processes. Production efficiency is aided by these systems' capacity to boost output, cut costs, boost quality, enabling real-time data collecting and monitoring of products. This aspect is anticipated to promote the use of these systems in order to boost revenues. The use of Nuclear Medicine also results in decreases in the amount of waste and energy used throughout the production process. For instance, putting a MES solution on a shop floor eliminates the need for paperwork and physical storage space while not requiring extra IT resources.

Threat:

Stringent regulatory guidelines

As the industry evolves, adherence to complex and evolving regulations becomes paramount. These guidelines encompass safety, efficacy, and ethical considerations, often requiring rigorous testing and approval processes for new technologies and radiopharmaceuticals. The time and resources needed for compliance can hinder innovation, delay product launches, and increase development costs. Struggling to meet these requirements might deter new entrants and limit market growth. Consequently, navigating the intricate landscape of regulatory constraints emerges as a substantial challenge, potentially impeding the swift advancement of nuclear medicine solutions.

COVID-19 Impact:

The COVID-19 pandemic had a significant impact on the nuclear medicine market. Elective procedures and routine imaging faced delays due to resource reallocation and safety concerns, leading to decreased patient volumes. Supply chain disruptions affected the availability of radiopharmaceuticals and equipment, causing fluctuations in the market. However, the crisis underscored the value of nuclear medicine for rapid disease diagnosis and treatment monitoring. Telemedicine and remote reporting gained traction, reshaping service delivery.

The positron emission tomography (pet) applications segment is expected to be the largest during the forecast period

The positron emission tomography (pet) applications segment is expected to have a lucrative growth. It enables precise visualization and quantification of metabolic and functional processes within the body. PET is crucial for oncology, aiding in early cancer detection, accurate staging, and monitoring treatment response. Neurology benefits from PET scans for diagnosing brain disorders like Alzheimer's and epilepsy. Cardiovascular diseases are assessed through PET's ability to evaluate blood flow and heart function. Moreover, PET facilitates the development of novel radiopharmaceuticals and supports research in drug discovery. Its non-invasive nature and quantitative data make PET a cornerstone for advancing personalized and targeted medical interventions.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. Hospitals in the nuclear medicine market serve as primary hubs for diagnosis, treatment, and research. Equipped with advanced imaging equipment like PET, SPECT, and gamma cameras, hospitals provide essential nuclear medicine services. They cater to a wide range of patients, offering precise disease detection, accurate staging, and therapy monitoring. Nuclear medicine departments within hospitals collaborate with multidisciplinary teams to enhance patient care, often integrating imaging with other medical specialties. Furthermore, hospitals contribute significantly to the development and evaluation of innovative radiopharmaceuticals and imaging techniques, fostering continuous advancements in nuclear medicine for improved patient outcomes.

Region with largest share:

During the forecast period, it is expected that the North American Nuclear Medicine market will continue to hold a majority of the market share due to its advanced healthcare infrastructure and research capabilities. The region's well-established medical facilities and academic institutions drive innovation in imaging technologies and radiopharmaceutical development. The high prevalence of chronic diseases, including cancer and cardiovascular disorders, fuels the demand for nuclear medicine services. North America's robust regulatory framework ensures safety and quality standards. The presence of key market players, collaborations with research organizations, and increasing investments in healthcare contribute to the region's leadership in nuclear medicine, making it a hub for cutting-edge diagnostic and therapeutic applications.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, due to its increasing healthcare investments, rising awareness of early disease detection, and a growing geriatric population drive the demand for advanced diagnostic and therapeutic solutions. The region's expanding healthcare infrastructure, coupled with improving economic conditions, fosters the adoption of nuclear medicine technologies. Moreover, Asia Pacific's diverse patient pool provides ample opportunities for clinical research and trials, contributing to the development of innovative radiopharmaceuticals and imaging techniques. With a blend of emerging markets and technological advancements, Asia Pacific is poised to play a significant role in shaping the future of nuclear medicine.

Key players in the market:

Some of the key players in Nuclear Medicine market include: Isotopia Molecular Imaging Ltd., Jubilant Draximage, Inc., Lantheus Holdings, Inc., Cardinal Health, Global Medical Solutions, Pharmalogic Holdings Corp., Shine Technologies, llc, Ire Elit, Eczacibasi-Monrol Nuclear Products, GE Healthcare, Bayer AG, Bracco Imaging S.P.A., Nordion Inc., Northstar Medical Radioisotopes, Isotope JSC, Siemens Healthineers, Yantai Dongcheng Pharmaceutical Group Co., Ltd. and Eckert & Ziegler.

Key Developments:

In March 2023, Life Healthcare acquired TheraMed Nuclear's non-clinical imaging operations in Gauteng with an aim to expand its geographical presence in South Africa.

In February 2023, Telix Pharmaceuticals Limited announced the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) in February 2021. This project aims to create and validate a generator-based theranostic compound for urologic oncology targeting PSMA and utilising the beta-emitting isotope rhenium-188 (188Re).

In January 2023, Nuclear medicines are a group of pharmaceutical drugs that contain radioactive isotopes. They are exclusive medicinal formulations with radioisotopes and are used in major clinical areas for diagnosis or therapy.

In November 2022, Curium announced that the US Food and Drug Administration (FDA) approved DaTscan (Ioflupane I 123 Injection) to assist in evaluating adult patients with suspected Parkinsonian Syndromes.

Types Covered:

  • Diagnostic Nuclear Medicine
  • Therapeutic Nuclear Medicine
  • Brachytherapy Isotopes
  • Other Types

Applications Covered:

  • Diagnostic Applications
  • Other Applications

End Users Covered:

  • Hospitals
  • Imaging Centers
  • Academic & Research Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nuclear Medicine Market, By Type

  • 5.1 Introduction
  • 5.2 Diagnostic Nuclear Medicine
    • 5.2.1 Single Photon Emission Computerized Tomography (SPECT) Radiopharmaceuticals
      • 5.2.1.1 Technetium-99m
      • 5.2.1.2 Iodine-123
      • 5.2.1.3 Thallium-201
      • 5.2.1.4 Gallium-67
    • 5.2.2 Positron Emission Tomography (PET) Radiopharmaceuticals
      • 5.2.2.1 Fluorine-18
      • 5.2.2.2 Rubidium-82
  • 5.3 Therapeutic Nuclear Medicine
    • 5.3.1 Alpha Emitters
      • 5.3.1.1 Radium-223
    • 5.3.2 Beta Emitters
      • 5.3.2.1 Iodine-131
      • 5.3.2.2 Yittrium-90
      • 5.3.2.3 Samarium-153
      • 5.3.2.4 Lutetium-177
      • 5.3.2.5 Rhenium-186
  • 5.4 Brachytherapy Isotopes
    • 5.4.1 Iodine-125
    • 5.4.2 Iridium-192
    • 5.4.3 Palladium-103
    • 5.4.4 Cesium-131
  • 5.5 Other Types

6 Global Nuclear Medicine Market, By Application

  • 6.1 Introduction
  • 6.2 Diagnostic Applications
    • 6.2.1 Single Photon Emission Computerized Tomography (SPECT) Applications
      • 6.2.1.2 Cardiology
      • 6.2.1.3 Bone Scans
      • 6.2.1.4 Thyroid Applications
      • 6.2.1.5 Pulmonary Scans
    • 6.2.2 Positron Emission Tomography (PET) Applications
      • 6.2.2.1 Oncology
      • 6.2.2.2 Cardiology
      • 6.2.2.3 Neurology
    • 6.2.3 Therapeutic Applications
      • 6.2.3.1 Thyroid Indications
      • 6.2.3.2 Bone Metastasis
      • 6.2.3.3 Lymphoma
      • 6.2.3.4 Endocrine Tumors
  • 6.3 Other Applications

7 Global Nuclear Medicine Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Imaging Centers
  • 7.4 Academic & Research Centers
  • 7.5 Other End Users

8 Global Nuclear Medicine Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Isotopia Molecular Imaging Ltd.
  • 10.2 Jubilant Draximage, Inc.
  • 10.3 Lantheus Holdings, Inc.
  • 10.4 Cardinal Health
  • 10.5 Global Medical Solutions
  • 10.6 Pharmalogic Holdings Corp.
  • 10.7 Shine Technologies, llc
  • 10.8 Ire Elit
  • 10.9 Eczacibasi-Monrol Nuclear Products
  • 10.10 GE Healthcare
  • 10.11 Bayer AG
  • 10.12 Bracco Imaging S.P.A.
  • 10.13 Nordion Inc.
  • 10.14 Northstar Medical Radioisotopes
  • 10.15 Isotope JSC
  • 10.16 Siemens Healthineers
  • 10.17 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • 10.18 Eckert & Ziegler

List of Tables

  • Table 1 Global Nuclear Medicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nuclear Medicine Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Nuclear Medicine Market Outlook, By Diagnostic Nuclear Medicine (2021-2030) ($MN)
  • Table 4 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computerized Tomography (SPECT) Radiopharmaceuticals (2021-2030) ($MN)
  • Table 5 Global Nuclear Medicine Market Outlook, By Technetium-99m (2021-2030) ($MN)
  • Table 6 Global Nuclear Medicine Market Outlook, By Iodine-123 (2021-2030) ($MN)
  • Table 7 Global Nuclear Medicine Market Outlook, By Thallium-201 (2021-2030) ($MN)
  • Table 8 Global Nuclear Medicine Market Outlook, By Gallium-67 (2021-2030) ($MN)
  • Table 9 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Radiopharmaceuticals (2021-2030) ($MN)
  • Table 10 Global Nuclear Medicine Market Outlook, By Fluorine-18 (2021-2030) ($MN)
  • Table 11 Global Nuclear Medicine Market Outlook, By Rubidium-82 (2021-2030) ($MN)
  • Table 12 Global Nuclear Medicine Market Outlook, By Therapeutic Nuclear Medicine (2021-2030) ($MN)
  • Table 13 Global Nuclear Medicine Market Outlook, By Alpha Emitters (2021-2030) ($MN)
  • Table 14 Global Nuclear Medicine Market Outlook, By Radium-223 (2021-2030) ($MN)
  • Table 15 Global Nuclear Medicine Market Outlook, By Beta Emitters (2021-2030) ($MN)
  • Table 16 Global Nuclear Medicine Market Outlook, By Iodine-131 (2021-2030) ($MN)
  • Table 17 Global Nuclear Medicine Market Outlook, By Yittrium-90 (2021-2030) ($MN)
  • Table 18 Global Nuclear Medicine Market Outlook, By Samarium-153 (2021-2030) ($MN)
  • Table 19 Global Nuclear Medicine Market Outlook, By Lutetium-177 (2021-2030) ($MN)
  • Table 20 Global Nuclear Medicine Market Outlook, By Rhenium-186 (2021-2030) ($MN)
  • Table 21 Global Nuclear Medicine Market Outlook, By Brachytherapy Isotopes (2021-2030) ($MN)
  • Table 22 Global Nuclear Medicine Market Outlook, By Iodine-125 (2021-2030) ($MN)
  • Table 23 Global Nuclear Medicine Market Outlook, By Iridium-192 (2021-2030) ($MN)
  • Table 24 Global Nuclear Medicine Market Outlook, By Palladium-103 (2021-2030) ($MN)
  • Table 25 Global Nuclear Medicine Market Outlook, By Cesium-131 (2021-2030) ($MN)
  • Table 26 Global Nuclear Medicine Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 27 Global Nuclear Medicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 28 Global Nuclear Medicine Market Outlook, By Diagnostic Applications (2021-2030) ($MN)
  • Table 29 Global Nuclear Medicine Market Outlook, By Single Photon Emission Computerized Tomography (SPECT) Applications (2021-2030) ($MN)
  • Table 30 Global Nuclear Medicine Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 31 Global Nuclear Medicine Market Outlook, By Bone Scans (2021-2030) ($MN)
  • Table 32 Global Nuclear Medicine Market Outlook, By Thyroid Applications (2021-2030) ($MN)
  • Table 33 Global Nuclear Medicine Market Outlook, By Pulmonary Scans (2021-2030) ($MN)
  • Table 34 Global Nuclear Medicine Market Outlook, By Positron Emission Tomography (PET) Applications (2021-2030) ($MN)
  • Table 35 Global Nuclear Medicine Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 36 Global Nuclear Medicine Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 37 Global Nuclear Medicine Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 38 Global Nuclear Medicine Market Outlook, By Therapeutic Applications (2021-2030) ($MN)
  • Table 39 Global Nuclear Medicine Market Outlook, By Thyroid Indications (2021-2030) ($MN)
  • Table 40 Global Nuclear Medicine Market Outlook, By Bone Metastasis (2021-2030) ($MN)
  • Table 41 Global Nuclear Medicine Market Outlook, By Lymphoma (2021-2030) ($MN)
  • Table 42 Global Nuclear Medicine Market Outlook, By Endocrine Tumors (2021-2030) ($MN)
  • Table 43 Global Nuclear Medicine Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 44 Global Nuclear Medicine Market Outlook, By End User (2021-2030) ($MN)
  • Table 45 Global Nuclear Medicine Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 Global Nuclear Medicine Market Outlook, By Imaging Centers (2021-2030) ($MN)
  • Table 47 Global Nuclear Medicine Market Outlook, By Academic & Research Centers (2021-2030) ($MN)
  • Table 48 Global Nuclear Medicine Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.